Sepsis and Infectious Outcomes for GLP-r Agonists in CKD plus Type 2 Diabetes

Clicks: 6
ID: 324161
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #51 of 103 articles by views in nephrology dialysis transplantation

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Chronic kidney disease (CKD) is associated with a higher risk of sepsis and poorer clinical outcomes compared to the general population. While GLP-1 receptor agonists (GLP-1RA) may confer protective effects against sepsis beyond their metabolic benefits in patients with diabetes, their effect in CKD patients remains unclear. This study aims to evaluate the association between GLP-1RA therapy and infectious outcomes in patients with CKD. Methods Using the TriNetX database, we conducted a retrospective cohort study of adults with CKD and type 2 diabetes mellitus initiating GLP-1RAs or dipeptidyl peptidase-4 inhibitors (DPP-4i) between January 2020 and May 2026. The primary outcome was sepsis. Secondary outcomes included all-cause mortality, septic shock, pneumonia, urinary tract infection, and COVID-19. Results After propensity score matching, 21 035 patients were included in each treatment group. Use of GLP-1RA was associated with a lower risk of sepsis compared with DPP-4i (HR = 0.72; 95% CI, 0.66–0.78). GLP-1RA use was also associated with lower risks of all-cause mortality (HR = 0.65; 95% CI, 0.61–0.70), pneumonia (HR = 0.81; 95% CI, 0.75–0.87), urinary tract infection (HR = 0.83; 95% CI, 0.79–0.88), and COVID-19 (HR = 0.84; 95% CI, 0.77–0.90). The risk of septic shock did not reach Bonferroni-corrected significance level despite being numerically lower (HR = 0.84; 95% CI, 0.73–0.96; P = 0.014). Conclusions In patients with CKD and type 2 diabetes mellitus, use of GLP-1RA is associated with lower risks of sepsis, all-cause mortality, pneumonia, urinary tract infection, and COVID-19 compared with DPP-4i, while the risk of septic shock was similar between groups.
Reference Key
openalex_W7201859221 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yu-Yang Tseng, Hsien-Yi Wang, Jui‐Yi Chen, Ming‐Yan Jiang, Chih‐Cheng Lai, Min‐Hsiang Chuang
Journal nephrology dialysis transplantation
Year 2026
DOI
10.1093/ndt/gfag175
URL
https://doi.org/10.1093/ndt/gfag175
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.